Z-DEVD-FMK peptide

Z-DEVD-FMK peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

DEVD, Asp-1 = Z-Asp(OMe), Glu-2 = Glu(OMe), Asp-4 = (OMe)-fluoromethylketone

Benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethylketone

4

95.62%

C₃₀H₄₁FN₄O₁₂

668.67

Synthetic

Powder

Z-DEVD-FMK is a cell-permeable, irreversible inhibitor of caspase-3 with an IC50 of 0.13 µM and no activity at cathepsin B and cathepsin L. Z-DEVD-FMK inhibits apoptotic cell death in many cell types including cancer cells, it is neuroprotective in rat hippocampus following seizures in vivo and local application of Z-DEVD-FMK after spinal cord injury in rats reduces secondary tissue injury and helps preserve motor function.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Ma et al (1998) Synergistic effects of caspase inhibitors and MK-801 in brain injury after transient focal cerebral ischaemia in mice. Br J Pharmacol. 124(4) 756 PMID: 9690868
• Henshall et al (2000) Involvement of caspase-3-like protease in the mechanism of cell death following focally evoked limbic seizures. J.Neurochem. 74 1215 PMID: 10693954
• Barut et al (2005) The neuroprotective effects of z-DEVD.fmk, a caspase-3 inhibitor, on traumatic spinal cord injury in rats. Surg Neurol. 64(3) 213 PMID: 16099247

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.